A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
نویسندگان
چکیده
منابع مشابه
Pirfenidone in idiopathic pulmonary fibrosis.
We read with interest the article of TANIGUCHI et al. [1] entitled ‘‘Pirfenidone in idiopathic pulmonary fibrosis’’. These authors have spearheaded the investigation of this novel antifibrotic agent for idiopathic pulmonary fibrosis, and their efforts are commendable. In an editorial that accompanied their manuscript, COLLARD [2] pointed out a number of shortcomings of the study that raise conc...
متن کاملPirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis.
Pirfenidone works. There have been four randomised placebo-control trials of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF); a phase II and phase III study in Japan, and two international multicentre phase III studies. In all four studies, patients treated with pirfenidone had slower rates of decline in lung volume (vital capacity (VC) in the Japanese studies and forced vi...
متن کاملPirfenidone in idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective therapy. A multicentre, double-blind, placebo-controlled, randomised phase III clinical trial was conducted in Japanese patients with well-defined IPF to determine the efficacy and safety of pirfenidone, a novel antifibrotic oral agent, over 52 weeks. Of 275 patients randomised (high-dose, 1,800 mg x day(...
متن کاملIdiopathic pulmonary fibrosis and pirfenidone.
T he last decade has seen important progress in the clinical investigation of idiopathic pulmonary fibrosis (IPF). Basic insights into mechanisms of fibroproliferation have been translated into novel investigational agents, networks of clinical centres capable of enrolling hundreds of patients in research studies have been developed, and multiple high-quality treatment trials have been successf...
متن کاملIPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible fibrotic lung disease that requires long-term treatment. Given the importance of adherence to treatment and management of adverse events (AEs), patients with IPF need long-term, high-quality support in living with their condition, and adhering to therapy so they can derive maximum benefit. The IPF Care Patient Suppo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pulmonary Therapy
سال: 2019
ISSN: 2364-1754,2364-1746
DOI: 10.1007/s41030-019-0096-8